Version 1
: Received: 6 April 2022 / Approved: 8 April 2022 / Online: 8 April 2022 (03:27:23 CEST)
Version 2
: Received: 5 June 2022 / Approved: 6 June 2022 / Online: 6 June 2022 (05:53:21 CEST)
How to cite:
Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints2022, 2022040069. https://doi.org/10.20944/preprints202204.0069.v2
Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints 2022, 2022040069. https://doi.org/10.20944/preprints202204.0069.v2
Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints2022, 2022040069. https://doi.org/10.20944/preprints202204.0069.v2
APA Style
Ishikawa, T., Kodama, E., Kobayashi, T., Azumi, M., Nozawa, Y., Iwanaga, A., Sano, T., & Honma, T. (2022). Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints. https://doi.org/10.20944/preprints202204.0069.v2
Chicago/Turabian Style
Ishikawa, T., Tomoe Sano and Terasu Honma. 2022 "Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device" Preprints. https://doi.org/10.20944/preprints202204.0069.v2
Abstract
Background:Transarterial chemoembolization (TACE) is the standard treatment for BCLC-B hepatocellular carcinoma (HCC). A novel glass membrane emulsification device (GMD) produces a high percentage of water/oil emulsions with homogeneous and stable droplets. There are few reports on the efficacy of GMD-conventional-TACE (GMD-c-TACE)；therefore, we aimed to evaluate the effectiveness of GMD-c-TACE. Methods:Seventy-one patients with HCC with tumor diameter <5 cm who underwent c-TACE with and without GMD were included in this study to investigate local recurrence and hepatic functional reserve. Results:The local recurrence rates of TACE without GMD were 3.0% at 6 months, 16.7% at 12 months, and 35.0% at 18 months, around where it plateaued. Hence, the local recurrence rates in the GMD-c-TACE group were 7.7% at 14 months and 23.1% at 20 months, respectively. Thus, GMD-c-TACE had a significantly lower local recurrence. Multivariate analysis showed that GMD-c-TACE could suppress local recurrence and maintain hepatic reserve. Conclusions: GMD-c-TACE allows dense lipiodol accumulation in the tumor and attainment of good local control. Additionally, the inhibition of the release of anticancer drugs may maintain hepatic reserve. GMD-c-TACE is useful in preventing local recurrence and is expected to become the standard treatment form of c-TACE in the future.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter: Toru Ishikawa
Commenter's Conflict of Interests: Author